BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Studies show that approximately 20% of all breast cancer patients have a breast tumor that tests positive for Human Epidermal Growth Factor Receptor 2, otherwise known as the HER2 gene. As such, treatments for breast cancer usually include drugs that target HER2. The drug Trastuzumab is a recombinan...

Descripción completa

Detalles Bibliográficos
Autores principales: Patra, Satyajit, Young, Vanesa, Llewellyn, Leslie, Senapati, Jitendra N, Mathew, Jesil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697482/
https://www.ncbi.nlm.nih.gov/pubmed/28843257
http://dx.doi.org/10.22034/APJCP.2017.18.8.2209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697482/
https://www.ncbi.nlm.nih.gov/pubmed/28843257
http://dx.doi.org/10.22034/APJCP.2017.18.8.2209

Ejemplares similares